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Reply to Singh
To the Editor—We read the letter from
Singh [1] with great interest, because she
outlined several important issues that may
not be easy to clarify. The recent article
by Arthurs et al. [2], which was not avail-
able when we wrote our review, suggests
that late-onset cytomegalovirus (CMV)
disease may not be as mild as has been
previously reported by others. In our long-
lasting experience with anti-CMV pro-
phylaxis [3], late-onset CMV disease was
perceived and evaluated as a relatively
mild event, at least in kidney transplant
recipients, with few symptoms and a be-
nign course after receipt of ganciclovir or
valacyclovir therapy. It should be noticed
that the figures reported by Arthurs et al.
[2] were unusually high: a 29% incidence
of late-onset CMV disease, compared with
incidences of 16% in the valacyclovir
group in the study by Lowance et al. [3]
and 17.2% (in the valganciclovir group)
and 18.4% (in the oral ganciclovir group)
in the pivotal study by Paya et al. [4]. In
our own experience, 17% of kidney trans-
plant recipients develop late-onset CMV
disease (data not shown). Although the
cause is not clear (because these transplant
recipients were at high immunological
risk), the relatively high figures reported
by Arthurs et al. [2] may have affected the
results regarding the impact of late-onset
CMV in terms of allograft loss or
mortality.
The discussion about the consequences
of late-onset CMV disease is more than
an academic debate. Indeed, it is aimed at
answering relevant questions regarding the
best means to prevent post-transplanta-
tion CMV disease. Data from a recent
meta-analysis indicated that both prophy-
laxis and preemptive treatment reduced
the incidence of CMV disease and of acute
transplant rejection; however, prophylaxis
without preemptive treatment did reduce
the incidence of bacterial and fungal in-
fections and death [5]. When prophylaxis
and preemptive treatments were com-
pared with one another, there was, indeed,
no statistically significant difference with
regard to efficacy in the prevention of
CMV disease [6, 7]. However, in the study
by Reischig et al. [6], there were slight and
statistically significant benefits in the pro-
phylaxis group with regard to CMV-
DNAemia at 12 months, incidence of bi-
opsy-proven acute rejection, and
CMV-associated costs. Moreover, in the
recent study by Kliem et al. [7], long-term
graft survival at 2, 3, and 4 years was sig-
nificantly improved in the prophylaxis
group. These recent data, together with the
simple use of prophylaxis after transplan-
tation, suggest that the prophylactic ap-
proach may become a more attractive
strategy to prevent CMV disease after or-
gan transplantation.
Finally, as mentioned by Singh [1], the
issue of the most appropriate duration of
antiviral prophylaxis will be partly solved
by the ongoing Improved Protection
Against Cytomegalovirus in Transplant
(IMPACT) study. If, among high-risk pa-
tients undergoing donor-positive/recipi-
ent-negative transplantations, the inci-
dence of late-onset CMV disease decreases
as the length of anti-CMV prophylaxis in-
creases, this may have a beneficial impact
on morbidity and mortality that would be
an important new step in defining the op-
timal CMV disease prevention strategies.
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